Please note, this OEL/ADE monograph also applies to perindopril erbumine (CAS RN 107133-36-8) and perindopril arginine (CAS RN 612548-45-5). Perindopril is indicated for high blood pressure and stabilization of cardiovascular risk. Perindopril acts as a prodrug of the diacid perindoprilat. It is an angiotensin-converting enzyme (ACE) inhibitor that is hydrolyzed by hepatic esterase to yield the active drug, perindoprilat. Perindoprilat reduces blood pressure by inhibiting the activity of ACE, which results in decreased plasma angiotensin II. A reduction in plasma angiotensin II decreases vasoconstriction and aldosterone secretion, but it increases plasma renin activity.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Perindopril, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.